Encompass Health
EHC
$108.08
+3.11%
Encompass Health Corporation is a leading provider of post-acute healthcare services in the United States, operating a national network of inpatient rehabilitation hospitals that specialize in treating patients recovering from strokes, neurological disorders, cardiac conditions, and complex orthopedic injuries. The company is a dominant pure-play operator in the inpatient rehabilitation facility (IRF) segment, distinguishing itself through a singular focus on high-acuity rehabilitative care and a geographically diversified portfolio. The current investor narrative centers on the company's ability to navigate a challenging labor and reimbursement environment while demonstrating resilient organic growth, as evidenced by recent quarterly revenue increases, and its commitment to returning capital to shareholders through consistent dividends and share repurchases.…
EHC
Encompass Health
$108.08
Related headlines
Investment Opinion: Should I buy EHC Today?
Rating & Thesis: Hold. EHC is a fundamentally sound company trapped in a negative momentum cycle, making it a 'Show Me' story where the valuation is compelling but requires a catalyst to reverse sentiment. The consensus analyst view is bullish, but the stock's persistent underperformance suggests the market disagrees.
Supporting Evidence: The stock trades at a forward P/E of 16.58x, a PEG ratio of 0.78 (implying undervaluation), and a Price/Sales of 1.80x. Revenue growth remains healthy at ~10% YoY, and profitability is robust with a net margin near 10%. The company generates substantial free cash flow ($439M TTM) and returns capital via dividends and buybacks. However, these positives are counterbalanced by a 1-year price decline of -7.3% and a technical picture showing the stock near the lower third of its 52-week range.
Risks & Conditions: The two biggest risks are continued negative momentum overwhelming fundamentals and a deterioration in reimbursement rates. This Hold rating would upgrade to a Buy if the stock demonstrates a sustained technical breakout above the $117 resistance level on strong volume, confirming a sentiment shift. It would downgrade to a Sell if quarterly revenue growth decelerates below 5% or if net margins contract below 8%. Relative to its own history and growth profile, the stock appears fairly valued to slightly undervalued, but it is not cheap enough to ignore the clear bearish momentum.
Sign up to view all
EHC 12-Month Price Forecast
EHC presents a dichotomy of strong fundamentals and weak price action. The base case of range-bound trading is most probable, as the stock needs time to rebuild investor confidence. The bullish scenario requires a clear fundamental catalyst to overpower the entrenched negative momentum, while the bearish scenario, though less likely, could unfold rapidly if key support fails. The stance is neutral due to this stalemate; it would turn bullish on a confirmed breakout above $117 with strong volume, or bearish on a breakdown below $93 with deteriorating margins.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Encompass Health's 12-month outlook, with a consensus price target around $140.50 and implied upside of +30.0% versus the current price.
Average Target
$140.50
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$86 - $141
Analyst target range
Analyst coverage for EHC is limited, with only 3 analysts providing estimates, which is low for a company of its market cap and suggests it may be under-followed by the broader institutional research community. The consensus leans bullish, with recent institutional ratings from firms like Barclays, UBS, and BofA Securities consistently reiterating 'Buy' or 'Overweight' equivalents throughout 2025 and early 2026, indicating sustained positive sentiment among covering analysts. The average EPS estimate for the forward period is $7.69, with a tight range between $7.65 and $7.75, pointing to high conviction in near-term earnings projections. The estimated revenue range for the forward period is between $7.90 billion and $7.98 billion, with an average of $7.935 billion. The narrow spread between the high and low targets for both EPS and revenue signals relatively low uncertainty and strong analyst agreement on the company's near-term financial trajectory. The pattern of reiterated bullish ratings without downgrades, as seen in the institutional ratings data from Barclays, UBS, and Keybanc, reinforces a stable and positive outlook from the analyst community covering the stock.
Bulls vs Bears: EHC Investment Factors
The evidence presents a classic value vs. momentum conflict. The bull case is grounded in strong fundamentals: resilient ~10% revenue growth, robust profitability, attractive valuation (PEG of 0.78), and consistent cash returns. The bear case is driven by severe technical damage, significant underperformance, high short interest, and a concentrated business model. Currently, the fundamental bull points appear stronger, as the stock's deep valuation discount seems to overprice the operational risks. The single most important tension is whether the company's stable cash flows and growth can overcome the pervasive negative market sentiment and technical downtrend that has persisted for over a year. The resolution of this sentiment shift, potentially catalyzed by continued earnings delivery, will determine the stock's direction.
Bullish
- Strong Revenue Growth & Profitability: Q4 2025 revenue grew 9.94% YoY to $1.54B, with net income of $146.1M and a robust net margin of 9.46%. This demonstrates resilient organic growth and disciplined cost control in a challenging environment.
- Attractive Valuation & Undervalued PEG: The stock trades at a forward P/E of 16.58x and a PEG ratio of 0.78, suggesting it is undervalued relative to its earnings growth rate. The current trailing P/E of 18.84x is near the lower end of its recent historical range.
- Consistent Cash Generation & Shareholder Returns: The company generated $439.2M in TTM free cash flow and an ROE of 23.22%. This strong cash flow supports a consistent dividend and share repurchases, as evidenced by the recent dividend declaration.
- Positive Analyst Sentiment & Stable Outlook: Covering analysts from Barclays, UBS, and BofA maintain 'Buy' or 'Overweight' ratings. Forward EPS estimates are tightly clustered around $7.69, indicating high conviction in near-term earnings stability.
Bearish
- Severe Long-Term Underperformance vs. Market: The stock is down 7.30% over the past year, underperforming the S&P 500 by over 36 percentage points. This reflects persistent negative momentum and deep investor skepticism about the sector or company prospects.
- Elevated Short Interest & High Volatility: A short ratio of 3.16 indicates significant bearish speculation, which can fuel sharp downdrafts. The stock has experienced a maximum drawdown of -26.22%, highlighting substantial downside volatility and a lack of sustained support.
- Leveraged Balance Sheet & Concentrated Model: A debt-to-equity ratio of 1.11 indicates moderate leverage. The business model is entirely concentrated in the Inpatient Rehabilitation segment, creating a lack of diversification and heightened exposure to regulatory or reimbursement risks.
- Limited Analyst Coverage & Low Visibility: Only 3 analysts provide estimates for EHC, which is low for a $10B+ market cap company. This suggests the stock is under-followed, potentially leading to lower liquidity and higher volatility due to information asymmetry.
EHC Technical Analysis
The stock is in a pronounced downtrend over the past year, evidenced by a 1-year price change of -7.30%, significantly underperforming the S&P 500's 29.04% gain. As of the latest close at $107.48, the price is trading at approximately 31% of its 52-week range (from $92.77 to $127.99), positioning it much closer to its annual low than its high, which suggests the stock is in a deep value zone but also reflects persistent negative momentum and investor skepticism. The stock has experienced a maximum drawdown of -26.22% over the provided period, indicating substantial downside volatility and a lack of sustained support levels during the selloff. Recent momentum shows a sharp but potentially fragile recovery, with the stock up 10.37% over the past month and 13.70% over the past three months, diverging positively from the longer-term downtrend. This short-term strength, which includes a 7.48% single-day surge on May 1st, could signal a technical rebound or mean reversion from oversold conditions, though it remains well below the peaks seen in late 2025. The stock's relative strength versus the market is mixed, showing underperformance over one year (-36.34%) but outperformance over three months (+9.56%), hinting at a potential shift in sentiment. Key technical support is firmly established at the 52-week low of $92.77, while major resistance sits at the 52-week high of $127.99. A decisive breakout above the recent local highs near $116-117 would be necessary to signal a more durable recovery, while a breakdown below the $92.77 support could trigger a new leg down. The stock exhibits elevated volatility, with an average daily volume of approximately 1.74 million shares and a short ratio of 3.16, indicating a significant level of bearish speculation that could fuel sharp rallies on any positive catalyst.
Beta
0.58
0.58x market volatility
Max Drawdown
-26.2%
Largest decline past year
52-Week Range
$93-$128
Price range past year
Annual Return
-7.6%
Cumulative gain past year
| Period | EHC Return | S&P 500 |
|---|---|---|
| 1m | +0.8% | +8.6% |
| 3m | -4.7% | +6.7% |
| 6m | -5.4% | +9.8% |
| 1y | -7.6% | +26.6% |
| ytd | +1.6% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EHC Fundamental Analysis
Revenue growth remains healthy and consistent, with the most recent Q4 2025 revenue of $1.5446 billion representing a 9.94% year-over-year increase. The multi-quarter trend shows steady sequential growth from $1.4554 billion in Q1 2025 to the Q4 level, indicating the core inpatient rehabilitation business is driving stable top-line expansion. The company's revenue is derived entirely from its Inpatient segment, which generated $4.3386 billion over an unspecified period, confirming the singular focus of the business model and the lack of segment diversification. Profitability is robust, with the company generating a net income of $146.1 million in Q4 2025, translating to a net margin of 9.46%. Gross margin for the quarter was 22.78%, while the operating margin stood at 18.35%, reflecting the high-service nature of the business. Margins have shown stability, with the net margin hovering between 8.5% and 10.4% over the last several quarters, demonstrating disciplined cost control despite industry-wide pressure on labor expenses. The balance sheet is leveraged but manageable, with a debt-to-equity ratio of 1.11 and a current ratio of 1.08, indicating adequate short-term liquidity. The company generates substantial cash flow, with trailing twelve-month free cash flow of $439.2 million and an ROE of 23.22%, highlighting efficient use of shareholder capital. The consistent generation of positive operating cash flow, which was $346 million in Q4 2025, provides the company with internal funding for growth investments, dividends, and share repurchases, reducing reliance on external financing.
Quarterly Revenue
$1.5B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.22%
Latest Quarter
Free Cash Flow
$439199999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EHC Overvalued?
Given the company's consistent profitability with positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 18.84x, while the forward PE is 16.58x, based on estimated EPS of $7.69. The forward multiple being lower than the trailing multiple suggests analysts expect earnings growth, with the market pricing in a forward earnings increase. Peer comparison is challenging as specific industry average multiples are not provided in the data. However, the stock's valuation can be contextualized by its own metrics: a Price-to-Sales ratio of 1.80x and an EV/EBITDA of 9.46x. The PEG ratio of 0.78, based on trailing figures, suggests the stock may be undervalued relative to its earnings growth rate if that growth is sustainable. Historically, the stock's own valuation has compressed. The current trailing PE of 18.84x is below the historical PE ratio of 18.20x reported for Q4 2025 and has declined from levels above 25x seen in mid-2025. This places the current valuation near the lower end of its recent historical range, which could indicate a value opportunity if fundamentals remain intact, or it may reflect the market's expectation of slower future growth or margin pressures.
PE
18.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 14x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: EHC operates with moderate financial leverage (Debt/Equity of 1.11) and adequate liquidity (Current Ratio of 1.08). The primary financial risk is not insolvency but margin compression; while net margins are a healthy 9.46%, they are susceptible to industry-wide labor cost inflation. A more significant risk is business model concentration—100% of revenue comes from the Inpatient Rehabilitation segment. This lack of diversification makes the company highly sensitive to changes in Medicare/Medicaid reimbursement rates or regulatory shifts in post-acute care, which could directly and disproportionately impact the entire revenue stream.
Market & Competitive Risks: The stock trades at a forward P/E of 16.58x, which is below its own historical average (previously above 25x), indicating valuation compression has already occurred. The key market risk is that this compression continues if the stock remains out of favor, trading closer to its 52-week low of $92.77. Its severe underperformance versus the S&P 500 (-36.34% over one year) suggests it is being treated as a value trap. Competitive risks include pressure from integrated health systems and potential consolidation among smaller rivals, though EHC's scale as a pure-play leader provides some defense.
Worst-Case Scenario: The worst-case scenario involves a combination of a reimbursement rate cut, a spike in labor costs eroding the ~18% operating margin, and a broader market selloff triggering flight from out-of-favor stocks. This could lead to multiple contractions and earnings misses, driving the stock to retest and break below its 52-week low of $92.77. Given the stock's history of a -26.22% max drawdown, a realistic adverse scenario from the current price of $107.48 could see a decline of 20-25%, landing in the mid-$80s, especially if the short interest of 3.16 fuels a cascading sell-off.
FAQ
The key risks are: 1) Market/Sentiment Risk: The stock is in a pronounced downtrend, underperforming the S&P 500 by over 36% in the past year, and could remain out of favor. 2) Regulatory/Reimbursement Risk: As a pure-play inpatient rehab provider, 100% of revenue is exposed to potential changes in government healthcare payment rates. 3) Operational Risk: Margin pressure from persistent industry-wide labor cost inflation could erode the current ~18% operating margin. 4) Financial Risk: Moderate leverage (Debt/Equity of 1.11) could amplify downside in a rising rate environment. The sentiment and regulatory risks are currently the most severe.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees range-bound trading between $105 and $117, as solid execution battles persistent negative momentum. The Bull Case (30% probability) targets $120 to $128, driven by earnings beats, a re-rating, and a short squeeze. The Bear Case (15% probability) warns of a drop to $85-$95 if support breaks and fundamentals deteriorate. The most likely outcome is the base case, predicated on the assumption that the company meets analyst EPS estimates of $7.69 but fails to catalyze a sustained bullish reversal.
EHC appears fairly valued to slightly undervalued based on its growth profile. The primary metric, the forward P/E of 16.58x, is below its own historical average (previously above 25x), suggesting compression. The PEG ratio of 0.78 (below 1.0) classically indicates undervaluation relative to earnings growth. Compared to the broader market, it trades at a discount, but this reflects sector-specific and company-specific risks. The valuation implies the market expects minimal growth or potential headwinds, creating a gap between the stock price and the company's demonstrated ~10% revenue growth and strong cash flow.
EHC is a good buy for a specific type of investor: a patient value investor seeking a fundamentally sound company trading at a discount. With a forward P/E of 16.58x and a PEG ratio of 0.78, the valuation is attractive. However, the stock has significantly underperformed the market (-7.3% over one year) and carries high short interest, indicating skepticism. It is not a good buy for momentum traders or those with a short-term horizon, as negative sentiment may persist. For a long-term investor willing to wait for a sentiment shift, the risk/reward is favorable, but timing entry is tricky.
EHC is far more suitable for a long-term investment horizon (2+ years) than for short-term trading. Its high short interest (3.16) and history of sharp drawdowns (-26.22% max) make it volatile and unpredictable in the short term. However, its stable revenue growth, cash generation, and shareholder returns are characteristics of a long-term holding. The valuation discount likely requires time to correct. Given the need for sentiment to reverse, a minimum holding period of 12-18 months is suggested to allow the fundamental story to potentially overcome the technical damage.